Oramed Pharmaceuticals ORMP Q4 2025 Financial Overview Calisa Right ALISR Climbs 923 Resistance at 059 in Focus 20260515 Spyre Therapeutics SYRE Q1 2026 Earnings Miss Sparks Concern Womens Health Receives Only 20 of RD Funding World Economic Forum Highlights 1 Trillion Opportunity Oil Market Calm Masks Growing Supply Shock as Iran Crisis Reshapes Global Flows US Premarket Movers May 15 2026 Key Stocks Under Watch National NSA Delivers Q1 2026 Beat EPS 016 vs 015 Expected Endurance Technologies IPO Opens Key Details on the Rs 1162 Crore Issue